A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

NCT Number	NCT04666610
Lead Sponsor	UCB Biopharma SRL
Conditions	Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Enrollment	153 participants
Start Date	2021-07-29
Primary Completion	2026-07-07 (estimated)
Study Completion	2026-07-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-04